Stockscreener 앱 받기
47.92
1.05%
-0.51
Bristol Myers Squibb Co 주식(BMY)의 최신 뉴스
Agilent, Bristol Myers win FDA nod for cancer test (A:NYSE) - Seeking Alpha
Questex’s Fierce Pharma Week Announces Star-Studded Lineup with Jamie-Lynn Sigler, James Van Der Beek, Selma Blair, Kelly Killoran Bensimon and John Duffield to Provide Powerful Stories of Resilience and Healing - GlobeNewswire Inc.
Bristol Myers Squibb Stock Surges on FDA Breakthrough Designation for Lung Cancer Drug Despite Ranking 217th in Trading Volume - AInvest
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Bristol Myers Squibb, SystImmune gets USFDA Breakthrough Therapy Designation for izalontamab brengitecan... - Medical Dialogues
Bristol Myers Squibb's Lung Cancer Drug Secures FDA Breakthrough Status - AInvest
Bristol Myers Squibb Company stock outlook for YEAR2025 Volume Leaders & AI Driven Stock Movement Reports - Newser
Israel issues first antitrust fine to a global pharmaceutical company - Global Competition Review
FESTIVAL ANNOUNCEMENT: 31st One Mind Music Festival (Feat. Train) Presented by Bank of America and Bristol Myers Squibb - Enidnews.com
Bristol Myers and SystImmune’s lung cancer drug gets FDA boost - Investing.com
The Zacks Analyst Blog Highlights Lowe's, Bristol-Myers Squibb, Marvell Technology and Kewaunee Scientific - Yahoo Finance
Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer – Company AnnouncementFT.com - Financial Times
Bristol Myers (BMY) Partners with Bain Capital to Create Immunology Therapies - uk.finance.yahoo.com
Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS - Benzinga
Lowe's, Bristol-Myers, and Marvell Technology: Key Research Reports - AInvest
Top Research Reports for Lowe's, Bristol-Myers & Marvell Technology - Yahoo Finance
Bristol-Myers Squibb’s Promising Phase 3 Alzheimer’s Study: Market Implications - TipRanks
Bristol-Myers Squibb’s New Study on NSCLC Treatment: Market Implications - TipRanks
Layoff Tracker: Bausch Health Closes California Site, Cuts 49 Employees - BioSpace
Bristol-Myers Squibb’s Promising Phase 3 Study on Deucravacitinib for Sjögren’s Syndrome - TipRanks
Bristol-Myers Squibb and Incyte’s Cancer Study Update: Market Implications - TipRanks
Pfizer and Bristol-Myers Squibb’s Promising Study on Multiple Myeloma Treatment - TipRanks
Bristol-Myers Squibb’s New Psoriasis Study: A Long-Term Safety Evaluation - TipRanks
Anal Cancer Market Is Going to Boom | Major Giants Merck & Co., Roche, Bristol-Myers Squibb, Pfizer - newstrail.com
Bristol-Myers Squibb stock price target lowered to $45 at Cantor Fitzgerald - Investing.com Nigeria
Testicular Cancer Market Analysis and Forecast Report 2025-2035 | Competitive Analysis of Bristol Myers Squibb, Pfizer, Eli Lilly, Merck, Novartis, Amgen, F. Hoffmann-La RocheResearchAndMarkets.com - Bluefield Daily Telegraph
Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda - uk.finance.yahoo.com
Can Bristol Myers Squibb Company lead its sector in growthHigh Yield Growth Opportunities - mustnews.co.kr
Hung Trinh: BioNTech SE and Bristol Myers Squibb Partner on Next-Gen Bispecific Antibody for Solid Tumors - Oncodaily
Bristol-Myers Squibb’s MYK-224 Study Termination: What Investors Need to Know - MSN
Yan Leyfman: FDA Accepts Bristol Myers Squibb's Breyanzi for Priority Review as a Potential Treatment for Relapsed MZL - Oncodaily
Jim Cramer on Bristol-Myers: “Have Not Been Recommending the Stock” - Insider Monkey
Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector? - MSN
Bristol Myers Squibb Named Top Dividend Stock With Insider Buying and 5.47% Yield (BMY) - Nasdaq
Bristol-Myers Squibb’s Promising Phase 3 Study on BMS-986278: A Potential Game-Changer for Pulmonary Fibrosis - TipRanks
Bristol Myers Squibb (NYSE:BMY) Cut to Neutral at Daiwa Capital Markets - Defense World
Car T Cell Therapy For Multiple Myeloma Market Growth to Accelerate in Forecast Period (2024-2032), DelveInsight Analyzes by DelveInsight | Johnson & Johnson, Gadeta, Bristol-Myers Squibb, Bluebird - Barchart.com
Stock Analysis | Bristol-Myers Squibb OutlookNavigating Weak Technicals Amid Mixed Fundamentals - AInvest
FDA Accepts Breyanzi sBLA from Bristol Myers Squibb and Grants It Priority Review for MZL - BioPharm International
Bristol Myers Squibb Q1 2025 slides: portfolio transformation gains momentum as guidance raised - Investing.com Nigeria
Bristol Myers Squibb Q1 2025 slides: portfolio transformation gains momentum as guidance raised By Investing.com - Investing.com South Africa
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
3 Dividend Stocks for August 2025 - Morningstar
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View - MSN
Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity (NYSE:BMY) - Seeking Alpha
BioNTech Outlines Development Plan For PD-L1xVEGF-Targeting BNT-327 - insights.citeline.com
Morgan Stanley Maintains a Sell Rating on Bristol-Myers Squibb Company (BMY) - Insider Monkey
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas - Yahoo Finance
BioNTech shares rise over 2% as Q2 revenue doubles, Bristol Myers deal bolsters outlook - Investing.com
Bristol-Myers Squibb: Is the 30% Pullback a Strategic Buy Opportunity? - AInvest
Bristol-Myers Squibb (BMY) Stock Analysis: Exploring a 22.84% Upside Potential with a Robust Dividend Yield - DirectorsTalk Interviews
Bristol-Myers Squibb (BMY) Is Down 8.7% After Lowering Guidance Amid Strategic Shift and Generic Pressure - simplywall.st
BRISTOL-MYERS SQUIBB CO USD2 CNV CUM PFD USD1 To Go Ex-Dividend On August 5th, 2025 With 0.5 USD Dividend Per Share - 富途牛牛
What makes Bristol Myers Squibb Company Equity Right stock price move sharplyExceptional earning trajectories - Jammu Links News
Bristol-Myers Squibb: Declines Have Gone Too Far (NYSE:BMY) - Seeking Alpha
Bristol-Myers Squibb Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Bristol-Myers Squibb (BMY) Gains FDA Nod for TYK2 Inhibitor Sotyktu - Insider Monkey
Bristol-Myers Squibb Reports Strong Q2 2025 Results - The Globe and Mail
Bristol-Myers Squibb: No Respect For Blowout EarningsBuy The Richer Dividend Yields - Seeking Alpha
Bristol-Myers Squibb Co (NYSE: BMY): What Matters Now - stocksregister.com
1.46%
1.18%
자본화:
|
볼륨(24시간):